Kass N E, Myers R, Fuchs E J, Carson K A, Flexner C
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Berman Institute of Bioethics, Baltimore, Maryland, USA.
Clin Pharmacol Ther. 2007 Aug;82(2):219-27. doi: 10.1038/sj.clpt.6100192. Epub 2007 Apr 4.
In clinical research, ethics review generally first examines whether study risks are reasonable in light of benefits provided. Through informed consent, then, prospective subjects consider whether the risk/benefit balance and procedures are reasonable for them. Unique ethics issues emerge in clinical research with healthy volunteers. Certain types of studies only recruit healthy volunteers as participants. Phase 1 studies, for example, including first time in human studies of investigational drugs and vaccines, generally are conducted in healthy volunteers. Although such research carries inherent and often unknown risks, healthy subjects provide the most efficient target population in which to conduct such research, as these volunteers generally are free of concurrent diseases or medications that could confound interpretation of toxicity. Other studies enrolling healthy volunteers often are simply looking for the most scientifically sound population for the study of normal human physiology.
在临床研究中,伦理审查通常首先根据所提供的益处来检查研究风险是否合理。然后,通过知情同意,潜在受试者会考虑风险/益处平衡以及程序对他们来说是否合理。在针对健康志愿者的临床研究中会出现独特的伦理问题。某些类型的研究只招募健康志愿者作为参与者。例如,1期研究,包括对研究性药物和疫苗的首次人体研究,通常在健康志愿者中进行。尽管此类研究存在内在且往往未知的风险,但健康受试者是进行此类研究的最有效目标人群,因为这些志愿者通常没有可能混淆毒性解读的并发疾病或药物。其他招募健康志愿者的研究通常只是在寻找研究正常人体生理学的最科学合理的人群。